InvestSMART

ARGENX SE (BRU: ARGX) - ETF Exposure

Current share price for ARGX : 66.900 € 2.4 (3.72%)+

Currency: EUR (€)

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It , was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

ARGX General Information +

BRU Code ARGX
Industry/Sector Biotechnology
Market Cap (€M) n/a
ARGX Share Price 66.900 €
Day High 67.200 €
Day Low 66.000 €
Last Close 64.500 €
ARGX Share Price Movement 2.40 € ( 3.72% )
Prices as at 18:00, 4 Mar 2018
+Security prices are at best end-of-day and are indicative only.

Already own an ETF? You may already have meaningful exposure to ARGX

ARGENX SE (ARGX) is held across 26 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when ARGX moves, funds like VNGS, ESTX, ESGI, VMIN and HEUR that hold it can move with it.

For more concentrated exposure, ETFs such as VNGS (Vaughan Nelson Global SMID Fund (Managed Fund)) allocate about 1.4% to ARGX , while the average exposure across all 26 ETFs that hold it is around 0.4% .

Top ETF holdings

Last updated: ETF data and holdings as at 12 September 2026

Own ARGX directly or through an ETF?

How does holding ARGENX SE (ARGX) shares directly compare to ETFs that include it?

ARGX Direct
VNGS
ASX
ESTX
ASX
ESGI
ASX
VMIN
ASX
HEUR
ASX
Holdings 1 company 78 holdings 50 holdings 247 holdings 215 holdings 234 holdings
ARGX Weight 100% 1.4% 1.2% 1.1% 1% 1%
Diversification Single Stock Broad Broad Broad Broad Broad
Annual Cost Brokerage only 1.12% p.a. 0.35% p.a. 0.55% p.a. 0.28% p.a. 0.56% p.a.
Approx. Yield - 1.72% 7.33% 2.75% 12.31% 4.32%
Star Ratings - star starstarstarstar starstarstar star starstar

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not ARGX's direct yield. Annual cost uses each ETF's MER.

ARGX Exposure on $10,000 investment

How a $10,000 investment in ARGENX SE (ARGX) one week ago compares with ETFs that hold it.

Security Investment type Current price 7-day price movement Dollar change Value today
ARGENX SE (ARGX) Direct share 66.900 € 2.92% +292 € 10 292 €
Vaughan Nelson Global SMID Fund (Managed Fund) (VNGS) Equity - Global Strategy 3.730 € -1.58% -158 € 9 842 €
Global X EURO STOXX 50 ETF (ESTX) Equity - Global 106.550 € -1.07% -107 € 9 893 €
VanEck MSCI International Sustainable Equity ETF (ESGI) Equity - Global 37.050 € -1.57% -157 € 9 843 €
Vanguard Global Minimum Volatility Active ETF (Managed Fund) (VMIN) Equity - Global Strategy 61.650 € -1.27% -127 € 9 873 €
Betashares Europe ETF-Currency Hedged (HEUR) Equity - Global 18.170 € -1.57% -157 € 9 843 €

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

ARGX Financial Summary

Operating Revenue Per Share Price to Operating revenue Price to free cash flow Earnings Yield PE Ratio Dividend Yield Forward Dividend Yield Forward Earnings Yield
14.85 € 57.50 € 71.90 € 2.64% 37.93 n/a n/a 3.71

ARGX Calendar of Events

Created Date Changed Date Event
04 August 2026 04 August 2026 Company Meeting

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.